TY - JOUR T1 - Comparing the efficacy of Avonex, Rebif and Betaferon in motor disability (Expanded Disability Status Scale) and relapsing rate of multiple sclerosis patients TT - مقایسه اثربخشی داروهای آونکس، ربیف و بتافرون برمیزان ناتوانی حرکتی (EDSS) و میزان عود بیماری در مبتلایان به مالتیپل اسکلروزیس JF - iau-tmuj JO - iau-tmuj VL - 17 IS - 3 UR - http://tmuj.iautmu.ac.ir/article-1-66-en.html Y1 - 2007 SP - 139 EP - 146 KW - Multiple sclerosis KW - Avonex KW - Betaferon KW - Rebif KW - EDSS(Expanded Disability Status Scale). N2 - Background: Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system (CNS) that is a leading cause of disability in young adults. The aim of the present study was to compare the relative efficacies of Avonex, Rebif and Betaferon in EDSS and relapsing rate in MS patients. Materials and methods: 126 patients with multiple sclerosis were randomly allocated to the three treatment groups. The first group received Avonex (47.6%), the second group received Rebif (28.5%), and the third group received Betaferon (23.8%). For all patients, first and final EDSS and relapsing rate was assessed. Results: The mean age of patients was 31.1±8.6 years and 80.2% of patients were female. Differences between mean of first and final EDSS were statistically significant in three groups (p M3 ER -